<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02401373</url>
  </required_header>
  <id_info>
    <org_study_id>GR2015VCT001</org_study_id>
    <nct_id>NCT02401373</nct_id>
  </id_info>
  <brief_title>A Phase I Trial to Evaluate Ad5-EBOV in Healthy Adult Africans in China.</brief_title>
  <official_title>A Phase 1, Dose-escalation, Open Clinical Trial to Evaluate Safety, Tolerability and Immunogenicity of the Recombinant Human Type 5 Adenovirus Vector Based Ebola Vaccine (Ad5-EBOV) in Healthy Adult Africans Aged Between 18-60 Years in China</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>First Affiliated Hospital of Zhejiang University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Beijing Institute of Bioengineering, Academy of Military Medical Sciences</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Tianjin Cansino Biotechnology Inc</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>First Affiliated Hospital of Zhejiang University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a single center, open, dose-escalation phase 1 clinical trial. This study will&#xD;
      determine the safety and side-effect profile, and immunogenicity of an investigational&#xD;
      Ad5-EBOV vaccine in Healthy Adult Africans aged between 18-60 years in China.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a single center, open, dose-escalation clinical trial. According to the Chinese&#xD;
      guidelines for vaccine clinical trial, the sample size of a phase 1 clinical trial should be&#xD;
      at least 20. In this study, a total of 60 participants will be included.30 participants will&#xD;
      be firstly recruited and assigned to receive the low dose Ad5-EBOV. After the safety of the&#xD;
      low dose vaccination is confirmed, another 30 participants will be recruited and assigned to&#xD;
      receive the high dose Ad5-EBOV.&#xD;
&#xD;
      The whole follow-up period for each participant will be 28 days.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>March 2015</start_date>
  <completion_date type="Actual">July 2015</completion_date>
  <primary_completion_date type="Actual">July 2015</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>A Phase I, Open Clinical Trial to Evaluate the Adenovirus Type 5 Vector Based Ebola Virus Disease Vaccine (Ad5-EBOV) in Healthy Adult Africans in China.</measure>
    <time_frame>From March to July, 2015</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">61</enrollment>
  <condition>Ebola Virus Disease</condition>
  <arm_group>
    <arm_group_label>low dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>30 participants will be firstly recruited and assigned to receive the low dose of Recombinant Human Type 5 Adenovirus Vector Based Ebola Vaccine (Ad5-EBOV).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>High dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>After the safety of the low dose vaccination is confirmed, another 30 participants will be recruited and assigned to receive the high dose of Recombinant Human Type 5 Adenovirus Vector Based Ebola Vaccine (Ad5-EBOV).</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Ad5-EBOV</intervention_name>
    <description>intramuscular injection</description>
    <arm_group_label>High dose</arm_group_label>
    <arm_group_label>low dose</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Aged between 18 and 60 years.&#xD;
&#xD;
          -  African in China.&#xD;
&#xD;
          -  Able to understand the content of informed consent and willing to sign the informed&#xD;
             consent&#xD;
&#xD;
          -  Able and willing to complete all the secluded study process during the whole study&#xD;
             follow-up period (about 1 month).&#xD;
&#xD;
          -  A body mass index (BMI) 18.5-35.0 kg/m2&#xD;
&#xD;
          -  Hemoglobin ≥110g/L for female, and ≥120g/L for male.&#xD;
&#xD;
          -  White blood cells (WBC) 4.0-10.0×109 cells/L&#xD;
&#xD;
          -  Total lymphocyte Count 0.8-4.5×109 cells/L&#xD;
&#xD;
          -  Platelets 100-300×109 cells/L&#xD;
&#xD;
          -  Alanine aminotransferase (ALT) 0-40U/L&#xD;
&#xD;
          -  Serum creatinine 44-106μmol/L&#xD;
&#xD;
          -  Active partial thromboplastin time (APTT) 20-40 seconds&#xD;
&#xD;
          -  Prothrombin time (PT) 10-14 seconds&#xD;
&#xD;
          -  Negative in HIV diagnostic blood test&#xD;
&#xD;
          -  Axillary temperature ≤37.0°C on the day of enrollment&#xD;
&#xD;
          -  General good health as established by medical history and physical examination.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Family history of seizure, epilepsy, brain or mental disease&#xD;
&#xD;
          -  Participant that has a medical history of any of the following: allergic history of&#xD;
             any vaccination or drugs, or allergic to any ingredient of the Ad5-EBOV, such as&#xD;
             mannitol.&#xD;
&#xD;
          -  Woman who is pregnant, breast-feeding or positive in β-HCG (human chorionic&#xD;
             gonadotropin) pregnancy test (urine) on day of enrollment, or become pregnant during&#xD;
             the next 6 months&#xD;
&#xD;
          -  Any acute fever disease or infections in last 7 days&#xD;
&#xD;
          -  Major congenital defects or not well-controlled chronic illness, such as asthma,&#xD;
             diabetes, or thyroid disease&#xD;
&#xD;
          -  Hereditary angioneurotic edema or acquired angioneurotic edema&#xD;
&#xD;
          -  Urticaria in last one year&#xD;
&#xD;
          -  Asplenia or functional asplenia&#xD;
&#xD;
          -  Platelet disorder or other bleeding disorder may cause injection contraindication&#xD;
&#xD;
          -  Faint at the sight of blood or needles.&#xD;
&#xD;
          -  Prior administration of immunodepressant or corticosteroids, antianaphylaxis&#xD;
             treatment, cytotoxic treatment in last 6 months&#xD;
&#xD;
          -  Prior administration of blood products in last 4 months&#xD;
&#xD;
          -  Prior administration of other research medicines in last 1 month&#xD;
&#xD;
          -  Prior administration of attenuated vaccine in last 1 month&#xD;
&#xD;
          -  Prior administration of inactivated vaccine in last 14 days&#xD;
&#xD;
          -  Current anti-tuberculosis prophylaxis or therapy&#xD;
&#xD;
          -  Any condition that in the opinion of the investigators may interfere with the&#xD;
             evaluation of study objectives&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Lanjuan Li</last_name>
    <role>Principal Investigator</role>
    <affiliation>First Affiliated Hospital of Zhejiang University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>First affiliated hospital of Zhejiang University</name>
      <address>
        <city>Hangzhou</city>
        <state>Zhejiang</state>
        <zip>310003</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>July 2015</verification_date>
  <study_first_submitted>March 24, 2015</study_first_submitted>
  <study_first_submitted_qc>March 26, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 27, 2015</study_first_posted>
  <last_update_submitted>July 15, 2015</last_update_submitted>
  <last_update_submitted_qc>July 15, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 16, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>First Affiliated Hospital of Zhejiang University</investigator_affiliation>
    <investigator_full_name>Lanjuan Li</investigator_full_name>
    <investigator_title>Academy of Engineering</investigator_title>
  </responsible_party>
  <keyword>Vaccines</keyword>
  <keyword>Ebola Virus Disease</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Virus Diseases</mesh_term>
    <mesh_term>Hemorrhagic Fever, Ebola</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

